Mouse anti Human Cytochrome P450 3A5
X2047M
ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry
Product group Antibodies
ReactivityHuman
TargetCYP3A5
Overview
- SupplierNordic-MUbio
- Product NameMouse anti Human Cytochrome P450 3A5
- Delivery Days Customer7
- Application Supplier NoteAntibody can be used for Western blotting (1-2 microg/ml) and immunohistochemistry on formalin-fixed, paraffin-embedded tissues (1-5 microg/ml). When used in conjunction with CYP3A7 (Cat. No. X2048M), can differentiate between the CYP3A family members, 3A5 and 3A7. Optimal concentration should be evaluated by serial dilutions.
- ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry
- Applications SupplierWestern Blotting;ELISA;Western Blotting;Immunohistochemistry
- Category SupplierPrimary antibodies
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDF18 P3 B6
- ConjugateUnconjugated
- Gene ID1577
- Target nameCYP3A5
- Target descriptioncytochrome P450 family 3 subfamily A member 5
- Target synonymsaryl hydrocarbon hydroxylase; CP35; CYPIIIA5; cytochrome P450 3A5; cytochrome P450 HLp2; cytochrome P450, family 3, subfamily A, polypeptide 5; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5; cytochrome P450-PCN3; flavoprotein-linked monooxygenase; microsomal monooxygenase; P450PCN3; PCN3; xenobiotic monooxygenase
- HostMouse
- IsotypeIgG1
- Protein IDP20815
- Protein NameCytochrome P450 3A5
- Scientific DescriptionCYP3A5; CYP450 3A5 (EC 1.14.14.1), Niphedipine oxidase, CYPIIIA5, P450-PCN3, HLp2
- Shelf life instructionSee expiration date on vial
- ReactivityHuman
- Reactivity SupplierHuman
- Reactivity Supplier NoteHybridoma produced by the fusion of splenocytes from BALB/c mice immunized with a synthetic peptide derived from the C-terminus of the human CYP3A5 protein and mouse myeloma Ag8563 cells.
- UNSPSC12352203
References
- 1. Kumarakasingham, M., et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin. Cancer Res. 11(10);3758-3765. 2. McCune, J.S., et al (2005). Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethlation. Drug Metab. Dispos. 33(7);1074-1081. 3. Kim, K.A., et al. (2007). Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Cin. Pharmacol. 47(1);87-93